KRAS and pancreatic ductal adenocarcinoma: In addition, we determined the effects of SLC25A21 on pancreatic ductal adenocarcinoma (PDAC) cells with KRAS mutation (AsPC-1 and MIA PaCa-2) or WT KRAS (BxPC-3) and found that SLC25A21 upregulation inhibited the proliferation and colony formation of the 2 KRAS-mutant PDAC cell lines, but not of BxPC-3 cells (Supplemental Figure 3).